SEEK ID: https://seek.lisym.org/people/139
Location:
Germany
Expertise: Not specified
Tools: Not specified
ORCID: Not specified

LiSyM-Krebs Partnering (Deutsches Krebsforschungszentrum) ; LiSyM network (Deutsches Krebsforschungszentrum) ; LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP) (Deutsches Krebsforschungszentrum) ; LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF) (Deutsches Krebsforschungszentrum) ; LiSyM Scientific Leadership Team (LiSyM-LT) (Deutsches Krebsforschungszentrum) ; Forschungsnetzwerk LiSyM-Krebs (Deutsches Krebsforschungszentrum) ; SMART-NAFLD (Deutsches Krebsforschungszentrum)
Related items
- Programmes (2)
- Projects (7)
- Institutions (1)
- Investigations (0+1)
- Studies (0+1)
- Assays (0+3)
- Data files (0+1)
- Models (1)
- SOPs (0+5)
- Publications (3)
- Presentations (1+1)
- Documents (2+2)
LiSyM-Krebs ist ein nationales Forschungsnetz zur Früherkennung und Prävention von Leberkrebs, das unter Verwendung des systemmedizinischen Forschungsansatzes die komplexen, dynamischen Prozesse der Krankheitsprogression analysiert, um ausgehend von den Erkenntnissen aus dem Forschungsnetz LiSyM die Entstehung von Leberkrebs besser zu verstehen, vorherzusagen und im besten Fall sogar zu verhindern. LiSyM-Krebs setzt die erfolgreichen Forschungsaktivitäten der BMBF-Vorgängerprogramme ...
Projects: LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, SMART-NAFLD, DEEP-HCC network, C-TIP-HCC network
Web page: Not specified
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
SMART-NAFLD : A Systems Medicine Approach to Early Detection and Prevention of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease
The massive increase in obesity is leading to an alarming rise in non-alcoholic liver disease (NAFLD). This development will lead to a dramatic increase in liver diseases such as hepatocellular carcinoma (HCC). A particular challenge is that NAFLD-associated HCCs, for reasons still unknown, not only occur in association with advanced liver fibrosis/cirrhosis, ...
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: Not specified
Organisms: Mus musculus, Homo sapiens
Forschungsnetzwerk zur Früherkennung und Prävention- LiSyM-Krebs
Ein Netzwerk von Klinikern, Wissenschaftlern und Datenmanagern hat sich zur Aufgabe gemacht, Methoden zu entwickeln, um Patienten mit einem hohen Risiko für ein Leberkarzinom frühzeitig, in Vorstadien der Tumorentwicklung, identifizieren zu können. Gemeinsam bilden sie das „Systemmedizinische Forschungsnetzwerk zur Früherkennung und Prävention von Leberkrebs“, LiSym-Krebs, das vom Bundesministerium für Bildung und Forschung ...
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: Not specified
Organisms: Homo sapiens
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
In chronic diseases, at some point the liver can suddenly stop functioning. This is called acute-on-chronic liver failure, or ACLF. This is the leading cause of death in liver patients and is often provoked by the use of transcription or freely available drugs or alcohol abuse. For this condition we need an effective treatment quickly. LiSyM-Pillar III researches the factors that contribute significantly to ACLF. What exactly happens then? Are there any early signs that would enable ACLF to be ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Homo sapiens, Mus musculus, Rattus norvegicus, Rattus rattus
This comprises the whole LiSyM network
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org
Start date: 1st Jan 2016
Organisms: Rattus norvegicus, Rattus rattus, Mus musculus, Homo sapiens
ODE model describes dynamics of IFNalpha-induced signaling in Huh7.5 cells for a time scale up to 32 hours after stimulation with IFNalpha. The model consists of an IFN receptor model, formation/degradation and cytoplasmic/nuclear shuttling of STAT1-homodimers, STAT1-STAT2-heterodimers and STAT1-STAT2-IRF9 (ISGF3) complexes. On top, formation of feedback proteins STAT1, STAT2, IRF9, USP18, SOCS1, SOCS3 and IRF2 and corresponding influences on IFNalpha signaling dynamics was incorporated. The model ...
Creators: Jens Timmer, Ursula Klingmüller, Daniel Seehofer, Marcus Rosenblatt, Krishna Kumar Tiwari, Frédérique Kok
Submitter: Olga Krebs
Model type: Ordinary differential equations (ODE)
Model format: SBML
Environment: Copasi
Organism: Not specified
Investigations: 1 hidden item
Studies: 1 hidden item
Assays: 1 hidden item
Abstract
Authors: Lorenza A. D’Alessandro, Ursula Klingmüller, Marcel Schilling
Date Published: 30th Jun 2022
Publication Type: Journal
DOI: 10.1042/BCJ20210548
Citation: Biochemical Journal 479(12):1361-1374
Abstract (Expand)
Authors: L. Adlung, P. Stapor, C. Tonsing, L. Schmiester, L. E. Schwarzmuller, L. Postawa, D. Wang, J. Timmer, U. Klingmuller, J. Hasenauer, M. Schilling
Date Published: 10th Aug 2021
Publication Type: Journal
PubMed ID: 34380040
Citation: Cell Rep. 2021 Aug 10;36(6):109507. doi: 10.1016/j.celrep.2021.109507.
Abstract (Expand)
Authors: F. Kok, M. Rosenblatt, M. Teusel, T. Nizharadze, V. Goncalves Magalhaes, C. Dachert, T. Maiwald, A. Vlasov, M. Wasch, S. Tyufekchieva, K. Hoffmann, G. Damm, D. Seehofer, T. Boettler, M. Binder, J. Timmer, M. Schilling, U. Klingmuller
Date Published: 23rd Jul 2020
Publication Type: Journal
PubMed ID: 32696599
Citation: Mol Syst Biol. 2020 Jul;16(7):e8955. doi: 10.15252/msb.20198955.
Jamboree presentation
Creators: Daniel Lill, Viktor Makarenko, Ursula Klingmüller, Jens Timmer
Submitter: Daniel Lill
Agenda for LiSyM-Cancer status seminar 2022
Creators: Olga Krebs, Susan Eckerle, Wolfgang Müller, Ursula Klingmüller, Ina Biermayer
Submitter: Olga Krebs
Investigations: No Investigations
Studies: No Studies
Assays: No Assays
Agenda Kickoff Meeting SMART-NAFLD 1-2 december 2021 in Heidelberg
Creators: Ursula Klingmüller, Ina Biermayer
Submitter: Olga Krebs
Investigations: No Investigations
Studies: No Studies
Assays: No Assays